Dialysis company shares plunge after Ozempic trial success vs. kidney trouble

📆 11/10/2023 4:59 PM
📰 MarketWatch

⏱ Reading Time:
16 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 97%

Australia News News

Australia Australia Latest News,Australia Australia Headlines

Steven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: @MKTWgoldstein.

The trial success of Novo Nordisk’s hit drug against kidney failure sent shares of a German kidney dialysis services firm plummeting on Wednesday.

Fresenius Medical Care shares XE:FME FMS slumped 23%, and shares of its part owner Fresenius XE:FRE lost 12%, after Novo Nordisk halted a trial of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease early because of its efficacy.

Write Comment

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Australia Australia Latest News, Australia Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Food Stocks Are Falling. Don't Blame Ozempic.Packaged-food stocks are in the red as of late, and it may indicate that consumers are shifting to fresh produce, meat, deli, and bakery products.
Source: MarketWatch - 🏆 3. / 97 Read more »